Bacteriobilia: a non-resolved problemCurrent status in outpatient parenteral antimicrobial therapy: a practical viewLiposomal formulations of amphotericin B: differences according to the scientific evidenceIs it possible to cure HIV infection?Optimization strategies in management of CMV infection in transplant patientsTherapeutic update in hepatitis CUpdate on Ebola virus infectionFilamentous fungal infections in immunosuppressed patients: prophylaxis and treatmentManagement of invasive candidiasis in non-neutropenic patientDuration of antimicrobial therapyCloxacillin-susceptible Staphylococcus aureus with high MIC to glycopeptides. Ever we use cloxacillin?Inhaled medication and inhalation devices for lung diseaseUsefulness of PK/PD parameters of antimicrobials in the treatment of complex and extremely-resistant infectionsTherapeutic options for carbapenemase-producing EnterobacteriaceaeLaboratory detection of carbapenemase-producing EnterobacteriaceaeApplicability of new diagnostic techniques in microbiology; technological innovationUpdate in Infectious Diseases 2015Noma/Cancrum oris: a neglected diseaseClinical usefulness of triazole derivatives in the management of fungal infectionsThe late media emergency of smallpox vaccine, news coverage of Spanish press (1999-2004)[Detection of antibacterial resistance by MALDI-TOF mass spectrometry].[Current management of imported severe malaria].Invasive pulmonary aspergillosis in non-neutropenic patientsCurrent status of drug treatment against the disease caused by the Ebola virusApproach to directed therapy after knowledge of the isolate: carbapenemase-producing Enterobacteriaceae, multidrug-resistant Pseudomonas aeruginosa and carbapenem-resistant Acinetobacter baumanniiDiagnostic and therapeutic approach of intraabdominal candidiasisHow should we approach Aspergillus in lung secretions of patients with COPD?Multidrug-resistant tuberculosis: current epidemiology, therapeutic regimens, new drugsResistant gram-negative bacteria. Therapeutic approach and risk factorsDeterminants of parasite drug resistance in human lymphatic filariasisEmpirical therapeutic approach to infection by resistant gram positive (acute bacterial skin and skin structure infections and health care pneumonia). Value of risk factorsResistance to the antimalarial drugsThe clinical microbiologist before the taxonomic changes in the genus ClostridiumEpidemiology of multi-drug resistant gramnegative bacilliMonotherapy vs. combined therapy in the treatment of multi-drug resistance gramnegative bacteriaUpdate in Infectious Diseases 2016Directed therapeutic approach to Staphylococcus aureus infections. Clinical aspects of prescriptionEpidemiology of the infection by resistant Gram-positive microorganismsOld and new antibiotics for therapy of multidrug resistant bacteriaFluoroquinolones: Non-antibacterial properties
P1433
Q26750491-FF8AE018-F01F-44B1-B1A9-2EECAF7F21C0Q26750786-B2AF9AE7-49D1-48C8-820E-8B99BED95511Q26775907-9E06E9C1-1091-4D04-9876-713CA14A81D6Q26781206-66D5EE2A-C0FA-48BF-A238-F2CAFDF01EC2Q26781209-B3B98CEA-5E40-4B37-A63D-462B0366F3D3Q26781210-8C26984D-5AE8-4A87-8284-D6054A248A24Q26781216-38662FB4-DA9A-43EA-9748-AB3DCDCCBD7CQ26781218-E353FD58-2E69-4284-9463-71D1EA825F8EQ26781221-3AAC38BD-A825-4531-9768-6EE83F2359A5Q26781222-D42B6C3A-2E21-44F1-B2DA-C05A9C751858Q26781226-0995BD41-1862-489F-874B-B57B162D81C8Q26781229-471A42D4-C8BA-410E-91B4-2F3767647486Q26781232-2844FE8D-FF00-4531-A326-3BBC888C334AQ26781234-8C79624A-8BBD-403E-8C9A-A600C6131555Q26781237-3DC89837-1765-449E-B8B9-310A4F91BDFCQ26781238-C1EFAFF7-AE24-4AA9-838D-A6D54372B210Q26781242-45655934-A670-46B8-A977-56FD80886BFFQ26781956-C6338439-1105-4909-9949-E40C3D216F2CQ26801041-791AED47-3C3E-4FB0-A116-52F4F4047673Q26823577-062AE26B-26E0-4108-AACE-35541BBD1882Q27687413-DE60BCC8-1EC1-4076-BE01-4B40C62BE76AQ27691327-527B5B85-E120-4411-B695-D7004B2150E7Q28065985-D8881776-AA97-4690-A3BB-15F6706A7234Q28066009-F74BCA6B-6251-42AA-AEA4-6359D276D766Q28066831-DCB62F69-75D1-42D2-853C-A4A6286C18BFQ28068181-AA6CC8BB-8521-475A-9FCA-076DA4A5648EQ28068350-0907596D-80C8-4B84-9867-74E1DD28DFFAQ28069554-22762160-3F61-4D28-AA90-D8F05AAAE193Q28069619-904D9B7E-52F5-46B7-819A-D257F2348926Q28069973-63A6943A-B34B-4C94-91E5-632551A39ECFQ28071286-7247FB32-2BE0-43B8-B96F-C4AB76AC103AQ28071341-105CF92F-4609-41DF-9432-591AC0D92EE0Q28072314-B32FBC90-1598-4032-BF60-395207859A1DQ28073848-0C1D3726-3388-4C52-8BA6-D211F06552B5Q28075705-E178068B-4D7A-4F42-A821-128B86E09577Q28077536-95DBAB55-B5E3-45C4-AE97-32776D457AB0Q28077911-8A8B88EC-AA78-4D97-84F2-2A0DFD062E64Q28077925-F7CDA96E-8D20-4EF8-A7F2-A2661FC799F0Q28078322-C0037EE3-59D7-4FD7-9E9E-142A331F20BCQ28078543-4FD2CB99-CC17-417C-80AA-7167547B5F11
P1433
description
journal
@en
revista científica
@es
rivista scientifica
@it
wetenschappelijk tijdschrift
@nl
wissenschaftliche Fachzeitschrift
@de
name
Revista Española de Quimioterapia
@ast
Revista Española de Quimioterapia
@br
Revista Española de Quimioterapia
@co
Revista Española de Quimioterapia
@da
Revista Española de Quimioterapia
@de
Revista Española de Quimioterapia
@en
Revista Española de Quimioterapia
@es
Revista Española de Quimioterapia
@fr
Revista Española de Quimioterapia
@id
Revista Española de Quimioterapia
@it
type
label
Revista Española de Quimioterapia
@ast
Revista Española de Quimioterapia
@br
Revista Española de Quimioterapia
@co
Revista Española de Quimioterapia
@da
Revista Española de Quimioterapia
@de
Revista Española de Quimioterapia
@en
Revista Española de Quimioterapia
@es
Revista Española de Quimioterapia
@fr
Revista Española de Quimioterapia
@id
Revista Española de Quimioterapia
@it
prefLabel
Revista Española de Quimioterapia
@ast
Revista Española de Quimioterapia
@br
Revista Española de Quimioterapia
@co
Revista Española de Quimioterapia
@da
Revista Española de Quimioterapia
@de
Revista Española de Quimioterapia
@en
Revista Española de Quimioterapia
@es
Revista Española de Quimioterapia
@fr
Revista Española de Quimioterapia
@id
Revista Española de Quimioterapia
@it
P1055
P1156
P1160
Rev. Esp. Quim.
P1476
Revista Española de Quimioterapia
@es